IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of “Moderate Buy” from Brokerages

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has been given an average rating of “Moderate Buy” by the seventeen research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and fifteen have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $48.6875.

IDYA has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Thursday, January 22nd. Truist Financial boosted their target price on IDEAYA Biosciences from $59.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Guggenheim restated a “buy” rating and set a $50.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, February 18th. Citigroup lifted their price target on IDEAYA Biosciences from $64.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Finally, Wall Street Zen downgraded shares of IDEAYA Biosciences from a “buy” rating to a “sell” rating in a research report on Saturday, February 21st.

IDEAYA Biosciences Price Performance

Shares of IDEAYA Biosciences stock opened at $31.67 on Friday. IDEAYA Biosciences has a 1 year low of $13.45 and a 1 year high of $39.28. The firm has a market cap of $2.78 billion, a price-to-earnings ratio of -24.18 and a beta of 0.10. The company has a 50-day moving average of $34.09 and a 200 day moving average of $30.74.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, February 17th. The company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.09. The business had revenue of $21.75 million during the quarter, compared to analysts’ expectations of $5.95 million. During the same quarter last year, the company posted ($1.49) EPS. IDEAYA Biosciences’s revenue for the quarter was up 55.7% compared to the same quarter last year. On average, equities analysts anticipate that IDEAYA Biosciences will post -3.07 EPS for the current year.

Hedge Funds Weigh In On IDEAYA Biosciences

A number of hedge funds have recently added to or reduced their stakes in IDYA. Farther Finance Advisors LLC boosted its stake in IDEAYA Biosciences by 171.1% during the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after purchasing an additional 580 shares during the last quarter. ANTIPODES PARTNERS Ltd boosted its position in shares of IDEAYA Biosciences by 49.4% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after buying an additional 380 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new stake in IDEAYA Biosciences in the 3rd quarter worth about $38,000. Global Retirement Partners LLC bought a new stake in IDEAYA Biosciences in the 4th quarter worth about $61,000. Finally, Abich Financial Wealth Management LLC purchased a new position in IDEAYA Biosciences in the 3rd quarter worth about $58,000. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.